Welcome to our dedicated page for Cyanotech news (Ticker: CYAN), a resource for investors and traders seeking the latest updates and insights on Cyanotech stock.
Cyanotech Corporation (CYAN) is a microalgae-focused manufacturer in the medicinal and botanical sector that regularly publishes detailed financial and operational updates. The company describes itself as a world leader in microalgae-based, high-value nutrition and health dietary supplement products, centered on its BioAstin Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica lines produced at its 96-acre facility in Kona, Hawaii.
On this news page, readers can follow Cyanotech’s quarterly and annual earnings announcements, where the company reports net sales, gross profit, operating income or loss, and net income or loss, along with commentary from management. These releases often discuss trends in bulk versus packaged sales, contract extraction revenue, inventory management, production efficiency, and gross margin performance.
Cyanotech’s news flow also covers strategic and operational themes such as tariff impacts on contract extraction competitiveness, macroeconomic conditions affecting demand, and initiatives in brand-building, e‑commerce channels and bulk ingredient markets. In addition, the company and its Nutrex-Hawaii subsidiary issue product-related news, including new formats like gummies for BioAstin Hawaiian Astaxanthin and Hawaiian Spirulina, reflecting ongoing product development within its microalgae-based portfolio.
Investors and observers can use this page to review management’s narrative around financial results, operational discipline, and the company’s focus on naturally farmed Hawaiian microalgae. For deeper detail, Cyanotech’s releases frequently direct readers to its Form 10‑K and Form 10‑Q filings with the U.S. Securities and Exchange Commission.
Cyanotech Corporation (Nasdaq: CYAN) reported robust financial results for the second quarter and first half of fiscal 2022, ended September 30, 2021. Net sales increased 10% to $9.42 million for Q2 and 15% to $18.38 million for the first six months. Gross profit margins improved to 39.9% in Q2 and 40.4% for the first half. Net income surged significantly to $970,000, or $0.15 per diluted share in Q2, up from $155,000 a year ago. The company attributed strong demand for its products and effective management of supply chain disruptions to these positive results.
Cyanotech Corporation (CYAN) reported strong financial results for the first quarter of fiscal 2022, ending June 30, 2021. Net sales reached $8,964,000, a 22% increase from $7,352,000 in the same quarter last year. Gross profit improved to $3,672,000 with a margin of 41.0%, up from 40.5%. Operating income rose to $619,000, compared to $268,000 the previous year. Net income also increased significantly to $520,000 or $0.08 per diluted share, compared to $138,000 or $0.02 per diluted share last year.
Cyanotech Corporation (CYAN) reported a slight increase in net sales for fiscal year 2021, totaling $32.3 million, up 1.4% from 2020. However, gross profit declined to $11.1 million, reflecting a 34.4% margin, down from 39.8% due to higher spirulina costs. The company generated $2.4 million in cash from operations, reducing debt by $1.7 million. For the fourth quarter, sales were $9.4 million, a 9.3% increase year-over-year, but net loss reached $200,000, or ($0.03) per diluted share.
Cyanotech Corporation (CYAN) reported financial results for Q3 and the first nine months of fiscal 2021. Q3 net sales decreased to $6.985 million, down by 6.9% year-over-year. Gross profit also fell to $2.071 million with a margin of 29.6%, a decline attributed to high-cost inventory. However, net income rose to $827,000, or $0.13 per diluted share, mainly due to Paycheck Protection Program loan forgiveness. For nine months, total sales were $22.907 million, while gross profit decreased to $8.347 million with a 36.4% margin.